Karus is an R&D-focused pharmaceutical company that is developing new small-molecule drugs for the treatment of chronic human diseases such as cancer and inflammation. The company's initial focus is the development of new, synthetically optimized histone deacetylase inhibitors (OS-HDI) that have gold-standard potency and the potential to become best-in-class treatments for a wide range of cancers, plus inflammatory and autoimmune diseases such as rheumatoid arthritis and psoriasis.
Karus has established a strong, experienced and multi-disciplinary commercial and scientific team that has helped the company make fast and efficient progress in its development programs. The Company's most advanced programs are based on novel, optimized analogues of a natural product HDI which Karus has engineered to improve its potency, safety and drug-like properties.
Karus's ability to convert key biological insights into novel small-molecule drugs has created therapeutics with blockbuster potential in major diseases such as cancer, inflammation and autoimmunity.
Simon Kerry, Chief Executive Officer
Karus Therapeutics Ltd
John Fairclough Centre
University of Southampton
Highfield
Southampton
Hampshire SO17 1BJ
United Kingdom